Recro Pharma Inc. (REPH) announced Monday morning that its second of two Phase III clinical trials of intravenous meloxicam, for the treatment of acute postoperative pain, met its primary endpoint.
from RTT - Before the Bell http://ift.tt/2gsavJW
via IFTTT
No comments:
Post a Comment